#USA #New York #Securities Law #Fulcrum Therapeutics #PRC2

Fulcrum Therapeutics in the Spotlight: Shareholder Investigation Underway

In a striking turn of events, Fulcrum Therapeutics, Inc. (NASDAQ: FULC) has witnessed a staggering drop of roughly 50% in stock value in just one trading session. This alarming decline followed the company's announcement on June 1, 2026, regarding significant class-wide safety concerns raised by the Food and Drug Administration (FDA) concerning PRC2-targeting agents. As a result, Fulcrum has decided to halt the development of its lead candidate, pociredir.

The aftermath of this announcement has left many investors in deep financial distress, prompting an investigation by SueWallSt. The investigation is focused on potential violations of securities law, particularly related to misleading statements made prior to the FDA's alert, which precipitated the stock market plunge.

Background on the Stock Decline

Before the FDA's warnings, Fulcrum's stock had been trading above $20, reflecting the company's promising prospects. However, following the alarming news, the share price plummeted to around $10. Investors who purchased shares at higher prices are now facing significant losses and are encouraged to take action to explore their legal rights.

An in-depth review of Fulcrum's February 2026 10-K filing revealed that certain executives held more than 264,000 shares between them, raising concerns about the timing and transparency of insider trades in relation to the company's publicly articulated positions.

Aside from insider trading disclosures, the 10-K also highlighted a long-term lease obligation of approximately $25.1 million for office and laboratory space, and a notable agreement with CAMP4 Therapeutics valued at up to $70 million in milestones and royalties. The exact upfront payment for this agreement has not been disclosed.

Key Investor Concerns

As the investigation unfolds, several critical questions arise that shareholders should consider:

• - Who can participate in the investigation? Investors who bought FULC stock and sustained losses may be eligible. It’s essential to have documented evidence of your purchase date and losses, regardless of whether you still own the shares.
• - What statements are potentially misleading? The crux of the investigation centers on whether Fulcrum Therapeutics made materially false claims regarding insider trading disclosures and the progress of the pociredir program, particularly since the FDA disclosed its safety concerns.
• - What actions can investors take? Shareholders are urged to gather brokerage documentation, including purchase dates and share quantities. Consulting with legal experts can provide valuable insight into their rights and options moving forward.
• - Is participation costly? Participation in the investigation is free of charge, as securities investigations typically operate on a contingency basis. This means no upfront fees or costs will be incurred by the investors.
• - What if shares have already been sold? Investors who sold their FULC shares at a loss may still qualify for the investigation, emphasizing the importance of timing and documented losses rather than ownership status.

Next Steps for Affected Investors

In light of these developments, investors impacted by the recent stock decline should consider reaching out to legal professionals who specialize in securities litigation. For those interested, Joseph E. Levi, Esq., and his team at SueWallSt can be contacted via email or phone for a no-obligation discussion regarding potential legal recourse. The continuous scrutiny of Fulcrum Therapeutics' practices aims to hold the company accountable while providing investors a chance to recover their financial losses.

The situation surrounding Fulcrum Therapeutics serves as a critical reminder of the volatility inherent in the biotech sector and the legal ramifications that can ensue following abrupt market changes spurred by regulatory announcements.